Related posts

This Week’s Stock Picks & BNN Top Picks Summary: NKE-N, CSU-T and 23 Stock and 1 ETF Top Picks (Mar 08-14)Feds hold rates, markets partially reboundBitcoin and gold flirt with highs, stocks fade
Investor Insights

This summary was created by AI, based on 48 opinions in the last 12 months.

Experts are divided on the outlook for Pfizer Inc. Some see value in the company's potential blockbuster drugs and strong dividend yield, while others are concerned about the impact of declining Covid-19 vaccine sales and patent expirations. Pfizer's recent acquisition and focus on cancer treatments are seen as promising, but there are also worries about the company's growth prospects and its ability to replace drugs coming off-patent.

Consensus
Divided
Valuation
Fair Value
TOP PICK
Pfizer Inc

A very contrarian pick. Why now? Company's pivoting from Covid to cancer. Unfortunately, cancer is a huge market with 1 in 3 being diagnosed. Very strong lineup of potential new blockbuster drugs, management confidence is high on them. Market underappreciates it. Estimated to grow earnings 14%. Trades at 10x, with nice yield of 5.96%.

Near the bottom, won't go much lower. Not if it will work, but when. You get a nice dividend. Tomorrow's winner.

(Analysts’ price target is $32.26)
biotechnology / pharmaceutical
WATCH
Pfizer Inc

Starting to look at it. Just made an acquisition. Growth rates starting to accelerate.

biotechnology / pharmaceutical
BUY
Pfizer Inc

Currently - stock is at a low price which presents a good buying opportunity. Excellent R&D department. Lots of products coming to the market. Dividend is able to help returns too. Obesity drugs also adding to bottom line (trendy product). 

biotechnology / pharmaceutical
DON'T BUY
Pfizer Inc

Hurting. He considers it in a downtrend, lower highs and lower lows, until proven otherwise. Proof that it's over is you start to see consolidation, little zig-zags on the chart. Could start soon, but hasn't yet.

biotechnology / pharmaceutical
DON'T BUY
Pfizer Inc

Great company, Covid saviour. Ran up on that, now falling off. Back to more normalized levels. Not his first choice. He owns MRK.

biotechnology / pharmaceutical
BUY
Pfizer Inc

Would recommend buying even with share price weakness. Does not believe market is pricing fairly. Dividend is safe. 

biotechnology / pharmaceutical
WATCH
Pfizer Inc
Value trap?

He was looking at it the other day. Trading where it was 30 years ago, despite a slew of acquisitions allowing it to tread water. Big dividend. Bought back shares. Pharma industry in general has been tough for 30 years. FDA has been tougher. Drugs coming out are more narrow-niche. Drug prices are under pressure globally. 

biotechnology / pharmaceutical
TOP PICK
Pfizer Inc

They're having a hangover, post-Covid, after selling vaccines, but those sales have plunged. But at $50 billion in sales, PFE remains a global pharma leader. Pays a 6% dividend. Shares are close to bottoming. Trades at only 12x PE vs. peers like Eli Lily at 70-80x.

(Analysts’ price target is $32.13)
biotechnology / pharmaceutical
COMMENT
Pfizer Inc

Pharma companies today are divided into the haves and have-nots. Eli Lilly and Vertex are in the 'haves' group. He owns Eli Lilly which could be the biggest of the Pharmas. Also Vertex looks good and has a new Cystic Fibrosis drug. Pfizer has little growth and the stock is under pressure. It pays a high dividend but offers no real dividend growth, He prefers lower paying dividend companies with significant dividend growth ahead rather than companies that pay high dividends now. With this theme in mind The ETF, RDVY, holds companies with the ability to grow dividends. His view is that it is a reflating world and that rates could go up more in the next cycle.

biotechnology / pharmaceutical
DON'T BUY
Pfizer Inc

Does not own shares. Recent share price erosion a good place to buy. Post Covid-19 demand has fallen, which has reduced revenues. Patent expiration also a major concern. Very old company, but would wait before buying. 

biotechnology / pharmaceutical
DON'T BUY
Pfizer Inc

Bought it last year for the 5.9% yield, but with Covid over (and vaccine sales gone), they have nothing. Shares have fallen in the past year. There was disappointment last year, but their obesity pill trial disappointed. Shares are washed out here. There are no expectations, though their drug pipeline is okay.

biotechnology / pharmaceutical
DON'T BUY
Pfizer Inc

Not convinced it's based. Pretty good dividend yield of 5.9% is one redeeming quality, appears fairly safe. Underperforming. May have over-invested in Covid-related ideas. Still great brand long term. Stay away for now.

biotechnology / pharmaceutical
TOP PICK
Pfizer Inc

Covid-19 vaccine business fading, but business strong. Valuation coming back down to reasonable levels. Dividend yield ~6%. Expecting further growth with excellent R&D investment. 

biotechnology / pharmaceutical
DON'T BUY
Pfizer Inc

Down 43% in 2023 and one of the S&P's dogs, falling sharply after Covid. Pfizer keeps facing patent cliffs for its drugs and hitting profit shortfalls. A comeback is possible, but election years made drugmakers targets. Pays a 5.6% dividend and their Seagen deal which could add an excellent cancer franchise. 

biotechnology / pharmaceutical
WATCH
Pfizer Inc

Not a great year, pullback in vaccine-related revenues, which are now normalizing. Reduced guidance every quarter this past year. Perhaps stock is washed out now. Patent cliffs. Buying companies and investing in R&D. Needs to see this is working.

biotechnology / pharmaceutical
Showing 1 to 15 of 809 entries

Pfizer Inc(PFE-N) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 12

Neutral - Hold Signals / Votes : 5

Bearish - Sell Signals / Votes : 17

Total Signals / Votes : 34

Stockchase rating for Pfizer Inc is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Pfizer Inc(PFE-N) Frequently Asked Questions

What is Pfizer Inc stock symbol?

Pfizer Inc is a American stock, trading under the symbol PFE-N on the New York Stock Exchange (PFE). It is usually referred to as NYSE:PFE or PFE-N

Is Pfizer Inc a buy or a sell?

In the last year, 34 stock analysts published opinions about PFE-N. 12 analysts recommended to BUY the stock. 17 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Pfizer Inc.

Is Pfizer Inc a good investment or a top pick?

Pfizer Inc was recommended as a Top Pick by on . Read the latest stock experts ratings for Pfizer Inc.

Why is Pfizer Inc stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Pfizer Inc worth watching?

34 stock analysts on Stockchase covered Pfizer Inc In the last year. It is a trending stock that is worth watching.

What is Pfizer Inc stock price?

On 2024-03-18, Pfizer Inc (PFE-N) stock closed at a price of $27.72.